Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.

Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W.

Am J Pathol. 2012 Mar;180(3):895-903. doi: 10.1016/j.ajpath.2011.11.030. Epub 2012 Jan 11.

2.

Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells.

Yu Q, Wang X, Wang L, Zheng J, Wang J, Wang B.

Scand J Gastroenterol. 2016 Oct;51(10):1220-6. doi: 10.1080/00365521.2016.1190399. Epub 2016 Jun 2.

PMID:
27251594
3.

Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.

Menon R, Deng M, Rüenauver K, Queisser A, Peifer M, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S.

J Pathol. 2013 Dec;231(4):505-16. doi: 10.1002/path.4274. Erratum in: J Pathol. 2014 May;233(1):101. Pfeifer, Martin [corrected to Peifer, Martin].

PMID:
24114522
4.

Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma.

Zhang B, Dong LW, Tan YX, Zhang J, Pan YF, Yang C, Li MH, Ding ZW, Liu LJ, Jiang TY, Yang JH, Wang HY.

Br J Cancer. 2013 Jul 9;109(1):14-23. doi: 10.1038/bjc.2013.293. Epub 2013 Jun 13.

5.

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM.

Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29.

6.

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.

Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN.

Mol Cancer Ther. 2006 Nov;5(11):2613-23. Epub 2006 Nov 6.

7.

Down-regulation of asparagine synthetase induces cell cycle arrest and inhibits cell proliferation of breast cancer.

Yang H, He X, Zheng Y, Feng W, Xia X, Yu X, Lin Z.

Chem Biol Drug Des. 2014 Nov;84(5):578-84. doi: 10.1111/cbdd.12348. Epub 2014 Jul 12.

PMID:
24775638
8.

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI.

Cancer Res. 2012 Dec 1;72(23):6142-52. doi: 10.1158/0008-5472.CAN-12-1335. Epub 2012 Sep 12.

9.

PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.

Kang M, Lee KH, Lee HS, Park YH, Jeong CW, Ku JH, Kim HH, Kwak C.

Prostate. 2016 Feb 15;76(3):273-85. doi: 10.1002/pros.23118. Epub 2015 Oct 26.

PMID:
26499308
10.

TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.

Ibuki N, Ghaffari M, Pandey M, Iu I, Fazli L, Kashiwagi M, Tojo H, Nakanishi O, Gleave ME, Cox ME.

Int J Cancer. 2013 Oct 15;133(8):1955-66. doi: 10.1002/ijc.28193. Epub 2013 May 6.

11.
12.

Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.

Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL.

Cancer Res. 2012 Feb 1;72(3):616-25. doi: 10.1158/0008-5472.CAN-11-2079. Epub 2011 Dec 7.

13.

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR.

PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.

14.

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y, Naito S.

Endocr Relat Cancer. 2011 Jul 11;18(4):505-17. doi: 10.1530/ERC-11-0017. Print 2011 Aug.

15.

Genomic strategy for targeting therapy in castration-resistant prostate cancer.

Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG.

J Clin Oncol. 2009 Apr 20;27(12):2022-9. doi: 10.1200/JCO.2008.17.2882. Epub 2009 Mar 16.

PMID:
19289629
16.

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.

Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H.

Oncotarget. 2016 Jan 19;7(3):3440-52. doi: 10.18632/oncotarget.6497.

17.

Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.

Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O.

Cancer Res. 2010 Feb 15;70(4):1606-15. doi: 10.1158/0008-5472.CAN-09-2984. Epub 2010 Feb 9.

18.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

19.

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.

Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W.

PLoS One. 2012;7(2):e31259. doi: 10.1371/journal.pone.0031259. Epub 2012 Feb 17.

20.

CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.

Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, Chen Z, Chen H, Clinton SK, Chan KK, Wang Q.

Cancer Res. 2011 Jul 15;71(14):4866-76. doi: 10.1158/0008-5472.CAN-10-4576. Epub 2011 May 18.

Supplemental Content

Support Center